TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06367283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will receive a placebo tablet identical to the metformin tablet
Study: NCT06233006

Intervention type: OTHER
Intervention: Assessment
Description: upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life

Intervention type: OTHER
Intervention: Assessment
Description: upper extremity functions (hand skills, hand and finger grip strength, reaction time, position sense, upper extremity strength and endurance) and health-related quality of life
Study: NCT04885413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib in Combination With Anti-PD1 Antibody
Description: Sintilimab： 200mg i.v., d1, 21days one cycle Niraparib： 200mg p.o qd，d1-d21, 21days one cycle
Study: NCT04803253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic accessory: 0109 - Universal Wrist
Description: The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic terminal device: 0112 - Hook
Description: The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand
Description: The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORTHOPUS prosthetic accessory: 0104 - body powered harness
Description: The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
Study: NCT04644692

Intervention type: OTHER
Intervention: Lung ultrasound
Description: A lung ultrasound before and at the end of the stress test.

Intervention type: OTHER
Intervention: Lung ultrasound
Description: A lung ultrasound before and at the end of the stress test.
Study: NCT05190289

Intervention type: OTHER
Intervention: Pre-existing degenerative factors of paraspinal muscles and bone mass
Description: Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass

Intervention type: OTHER
Intervention: Pre-existing degenerative factors of paraspinal muscles and bone mass
Description: Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
Study: NCT06471153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment Program Based on BASNEF Model
Description: Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Health Education
Description: Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
Study: NCT06133569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReDirection
Description: Self help program based on principles for cognitive behavioral therapy
Study: NCT06598774

Intervention type: OTHER
Intervention: Assessment of head posture:
Description: Head posture was assessed using photographic methods and craniovertebral angle

Intervention type: OTHER
Intervention: Assessment of head posture:
Description: Head posture was assessed using photographic methods and craniovertebral angle
Study: NCT06042036

Intervention type: OTHER
Intervention: Spontaneous mode of mechanical ventilation
Description: any mode of mechanical ventilation classified as spontaneous or proportional, mainly pressure support ventilation, but also CPAP, APRV, NAVA, PAV+
Study: NCT06598774

Intervention type: OTHER
Intervention: Assessment of Cervical Pain Pressure Threshold
Description: The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).

Intervention type: OTHER
Intervention: Assessment of Cervical Pain Pressure Threshold
Description: The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).
Study: NCT05026684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cost handout
Description: Patients will be given a personalized cost handout to make transparent the full costs to Veterans of different types of ambulatory visits in order to optimize the value of their health care investments.
Study: NCT06598774

Intervention type: OTHER
Intervention: Assessment of general cervical mobility
Description: Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.

Intervention type: OTHER
Intervention: Assessment of general cervical mobility
Description: Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.
Study: NCT05083312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APT-1011
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo orally disintegrating tablet
Study: NCT05472922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of MiniMizer Gastric Ring
Description: Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB
Study: NCT06598774

Intervention type: OTHER
Intervention: Assessment of upper cervical mobility
Description: It will be assessed using the CROM device and the flexion-rotation test.

Intervention type: OTHER
Intervention: Assessment of upper cervical mobility
Description: It will be assessed using the CROM device and the flexion-rotation test.

Intervention type: OTHER
Intervention: Assessment of Body Awareness
Description: Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.

Intervention type: OTHER
Intervention: Assessment of Body Awareness
Description: Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.
Study: NCT06602128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Breathing Exercise Application Group
Description: The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
Study: NCT05472922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal MGB-OAGB
Description: No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB
Study: NCT06606769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise training; twice a week for 12 months
Study: NCT05188404

Intervention type: BEHAVIORAL
Intervention: Choice of cannabis product
Description: Participants choose and purchase their own cannabis product
Study: NCT06721806

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP & bone regeneration
Description: PRP effect on bone healing

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PRP & bone regeneration
Description: PRP effect on bone healing
Study: NCT06719557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Oral capsule (extended)
Study: NCT06496867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Internal Fixation
Description: Early internal fixation of the LC1 fragility fracture of the pelvis will be defined as percutaneous anterior and/or posterior pelvic internal fixation with cannulated screw(s), medullary implant(s), or sacroiliac joint fusion device(s). The implant number, design, diameter, thread type (fully-threaded or partially-threaded), sacral segment (S1, S2, S3, or any combination there of), length, trajectory including sacroiliac or transsacral-transiliac, application with or without a washer, and ingrowth or ongrowth surface designs will be at the discretion of the treating surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nonoperative Care with Early Rehabilitation
Description: Nonoperative care with early rehabilitation will consist of nonoperative treatment of the pelvis fracture, including early consultation of the physical therapist, physiotherapist, or local equivalent rehabilitation provider at the time of randomization for a first attempt at mobilization of the patient within 24 hours of randomization. Patients who are unable to ambulate with assistance after five or more days of attempted mobilization by rehabilitation providers may be considered for delayed internal fixation treatment at the discretion of the patient and the treating surgeon. Delayed internal fixation after five or more days of attempted mobilization by rehabilitation providers will not be considered a treatment crossover event.
Study: NCT04846543

Intervention type: OTHER
Group type: OTHER
Intervention: MRI Scan
Description: MRI scan
Study: NCT06305793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG (intravenous immunoglobulin)
Description: Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
Study: NCT05164614

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-102 (80 μg)
Description: RaniPill capsule containing PTH with doses of 20 and 80 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forteo
Description: A commercial formulation of PTH for SC control (20 µg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-102 (20 μg)
Description: RaniPill capsule containing PTH with dose of 20μg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-102 (20 μg)
Description: RaniPill capsule containing PTH with dose of 20μg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-102 (20 μg)
Description: RaniPill capsule containing PTH with dose of 20μg
Study: NCT02219373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.
Study: NCT05747105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The 16-week protocol includes 11 total individual visits that integrate applicable elements of Cognitive Behavioral Therapy for Insomnia (CBT-I) and health behavior change theory. The first 6 weeks include weekly sessions (\~45 minutes each) focused on psychoeducation about sleep, goal-setting and self-monitoring, stimulus control, addressing cognitive and somatic arousal, sleep hygiene, and challenging negative thoughts about sleep. Sleep restriction will also be used in specific cases where sleep efficiency is low (\<85%). The remaining 10 weeks include briefer biweekly visits (5 visits, \~15-20 minutes each) to reinforce health behavior change strategies through topics such as problem-solving barriers, utilizing social support, identifying setbacks and creating an action plan, and relapse prevention. Self-reported sleep diary data and subjective sleepiness will be collected at each visit.
Study: NCT05855603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase \>20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase \<10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent pacemaker therapy
Description: All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
Study: NCT02219373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxcarbazepine
Description: Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
Study: NCT05004883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation of Cues Enhanced
Description: ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education, Stress Management and Social Support
Description: Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
Study: NCT05361915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abivertinib
Description: Abivertinib is a small molecule inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abivertinib
Description: Abivertinib is a small molecule inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Hormone-based chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Hormone-based chemotherapy
Study: NCT04995601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Health MAC
Description: The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
Study: NCT06305793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG Placebo
Description: Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG Placebo
Description: Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Care
Description: Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Care
Description: Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
Study: NCT05196074

Intervention type: OTHER
Intervention: Acute hypoxemic respiratory failure patients on VV-ECMO
Description: To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.
Study: NCT06337773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-weeks's on-line precision nursing education program
Description: The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
Study: NCT06308796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of CaP dental mousse
Description: Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.